In spite of advancements in perinatal care, bronchopulmonary dysplasia (BPD) remains a major cause of morbidity in premature babies with birth weights of less than 1000g (1) (2) (3) . BPD is the chronic lung disease that results from mechanical ventilation and oxygen therapy to treat acute respiratory failure in preterm infants (4) . Perinatal lung injury during the late canalicular stage disrupts the normal sequence of lung development, resulting in the histological pattern of alveolar simplification (larger but fewer alveoli with decreased septation), and impaired vascular growth (5, 6) and can be complicated by pulmonary hypertension (7) . However, the mechanisms that regulate normal alveolar development and the mechanisms that disrupt lung growth in premature infants are unknown. Currently, with no treatment for BPD, neonatologists are faced with a major therapeutic challenge (8) .
Recent evidence suggests a link between angiogenesis, the formation of blood vessels, and alveolarization (9) . Various animal models of impaired alveolar development also display abnormal lung vascular development. Rat pups exposed to high oxygen levels (60-95%) during the alveolar period have decreased alveolarization associated with decreased number of capillaries/mm 2 , increased muscularization of peripheral arteries and medial hypertrophy of muscular arteries (10) (11) (12) (13) (14) . Similar findings exist in dexamethasone-induced inhibition of alveolarization (15) and in Fawn-hooded rat pups, a rat-strain that develops spontaneous pulmonary hypertension as it ages (16) . Lung histology of premature baboons (17, 18) and lambs (19) treated similarly to human preterm infants have arrested alveolar development and decreased pulmonary capillary vasculature, features observed, at autopsy, in infants who died with BPD (20) . These findings suggest that vascular-specific growth factors are likely to play key roles during normal and impaired alveolar development.
Vascular endothelial growth factor (VEGF) is an angiogenic growth factor crucial for proper vascular development (21) . Recent data suggest that VEGF-driven angiogenesis contributes to lung development. Decreased lung VEGF levels have been observed in experimental (22) and human BPD (23) . Pharmacological and genetic inhibition of VEGF signaling results in reduced alveolarization in the neonatal rat (24, 25) . Adenovirus-mediated VEGF gene transfer preserves normal lung growth in the oxygen-induced BPD model in newborn rats (26) .
VEGF-induced angiogenesis is in part mediated by nitric oxide (NO) (27) . NO plays an important role in regulating pulmonary vascular tone during transition at birth (28) , but recent evidence suggests that NO also promotes structural changes in the developing lung including branching morphogenesis (29) and alveolarization (30) . Moreover, inhaled NO preserves normal lung growth in several neonatal animal models with structural and functional features of BPD (31, 32) . Recent clinical trials suggest that early treatment with inhaled NO may decrease the risk of BPD in premature infants with acute respiratory failure (33, 34) . Thus, the VEGF pathway may promote angiogenesis via an increase in NO production in the developing lung. NO stimulates the production of guanosine 3',5'-cyclic monophosphate (cGMP). cGMP is catabolized by phosphodiesterase enzymes (PDE). We hypothesized that Sildenafil, a cGMPspecific PDE5 inhibitor, would promote angiogenesis and reduce hyperoxia-induced lung injury in newborn rats. Our data show that Sildenafil increased pulmonary capillary density, preserved alveolar growth and alleviated echographic and structural signs of pulmonary hypertension, suggesting that the NO-cGMP pathway may be an effective target to protect the lung from alveolar damage. Some of the results of these studies have been previously reported in the form of an abstract (35) . 
Methods

Animal model. All procedures and protocols were approved by the Animal Health Care
Committee of the University of Alberta. From birth to postnatal age 14 (P14), Sprague-Dawley rat pups were exposed to normoxia (21%, control group) or hyperoxia (95% O 2 , BPD-group) in sealed Plexiglas chambers (BioSpherix, Redfield, NY) with continuous oxygen monitoring. Dams were switched between the hyperoxic and normoxic chambers every 48 hours to prevent damage to their lungs (36) . Litter size was adjusted so that all cages had an equal number of pups to control for effects of litter size on nutrition and growth. Rat pups were euthanized at P14 using an intraperitoneal injection of pentobarbital and lungs and heart were processed according to the performed experiments.
Experimental Protocol. Newborn rat pups were randomized to 3 groups: 1) normoxia (21%, control group), 2) hyperoxia (95% O 2 , BPD-group), and 3) hyperoxia+Sildenafil. Sildenafil (100 mg/kg) was administered to hyperoxic rat pups daily from birth to P14 via subcutaneous injection.
Preliminary dose-response studies using 2 and 20mg/kg/d had no protective effect on alveolar structures. Consequently, a larger dose of 100mg/kg/day was used for this study based on the effective Sildenafil dosage reported in other rodent studies. While considerably higher than the dose appropriate for humans, the dose we utilized had been shown in chronic in vivo studies in rats, to yield mean free plasma concentrations comparable to levels obtained in humans at doses of 1 mg/kg/d (37). This reflects the near 100-fold higher rate of metabolism of sildenafil in rats (38) . Barium-gelatin angiograms and arterial density counts. A barium-gelatin mixture (60ºC) was injected at 70 mmHg pressure in the main pulmonary artery until surface filling of vessels with barium was seen uniformly over the surface of the lung (40) . The main pulmonary artery was tied off under pressure, the lungs were inflation fixed with formaldehyde, the right cranial lobe was embedded in paraffin, and sections were cut and stained with hematoxylin and eosin. Barium-filled pulmonary arteries were counted per high-powered field (x100 magnification). Lungs of 4 animals/group, five sections/lung and ten high-power fields/section were counted.
Echo-doppler. Pulmonary hypertension was assessed using echo-doppler (SONOS 5500, Philips
Medical Systems) to measure the pulmonary arterial acceleration time (PAAT) (41, 42) . 
Results
Sildenafil promotes vessel formation in vitro.
In an in vitro model of angiogenesis, HPAEC form endothelial cord-like structures on matrigel ( Figure 1 ). Hyperoxia (95%) significantly reduced the endothelial network formation by HPAEC as compared with control, room air exposed HPAEC. Inhibition of cGMP inactivation using the cGMP-specific PDE5 inhibitor Sildenafil (10 -4M ) restored a dense capillary network in hyperoxia.
Sildenafil improves lung angiogenesis in hyperoxia-induced BPD in newborn rats.
Hyperoxia-exposed rat pups showed a significant decrease in pulmonary capillary density compared to normoxic rat pups, as observed in barium angiograms (Figure 2 ). Sildenafil-treated rat pups had higher capillary density than untreated hyperoxic rat pups.
Sildenafil improves alveolarization in hyperoxia-induced BPD in newborn rats.
Rat pups exposed to hyperoxia from birth to postnatal age 14 (P14) displayed the characteristic features of alveolar simplification, with larger and fewer alveolar airspaces and decreased septation as compared with normoxic animals (Figure 3 ). Sildenafil preserved alveolar growth in hyperoxic rats as assessed by the RAC.
Sildenafil reduced pulmonary hypertension associated with oxygen-induced lung injury.
Chronic exposure to hyperoxia was associated with a significant decrease in the PAAT ( Figure   4A ) and an increase in RVH and MWT of small pulmonary arteries ( Figure 4B and C). Sildenafil attenuated these functional and structural features of pulmonary hypertension as indicated by the increase in mean PAAT, reduction in RV/LV+S, and decrease in MWT.
Sildenafil-induced alveolar and vascular growth is associated with increased cGMP levels.
Hyperoxic rat pups had increased levels of cGMP compared to normoxic rats ( Figure 5 ).
Consistent with Sildenafil's mechanism of action as a cGMP-specific PDE5 inhibitor, the concentration of cGMP was further increased in hyperoxic rats treated with Sildenafil.
Discussion
This study shows that Sildenafil prevents lung injury and pulmonary hypertension in experimental oxygen-induced BPD in newborn rats. In vitro, Sildenafil preserves a rich endothelial network in hyperoxic-exposed HPAEC. In vivo, Sildenafil increases pulmonary capillary density, preserves alveolar growth and alleviates echographic and structural signs of pulmonary hypertension. Our findings suggest a role for the NO-cGMP pathway in angiogenesis and alveolarization in the developing lung. This pathway may be an effective target to protect the lung from impaired alveolar development.
Early observations by Liebow showed that the alveolar septa in emphysema were remarkably thin and almost avascular (44) . He postulated that a reduction in the blood supply of the small precapillary blood vessels might induce the disappearance of alveolar septa. Despite this early observation, pulmonary vessels were thought for many years, to be passive by-standers in lung development, following the branching pattern of the airways. Recent data however suggest that VEGF/NO-driven lung angiogenesis actively participates in alveolar growth (25, 30) and homeostasis throughout adulthood (45) . In preterm infants, inhaled NO promising results as a prophylactic therapy for BPD (33, 34) . Thus, we hypothesized that manipulating a downstream target of NO, specifically cGMP, would have similar beneficial effects on lung growth. Blockage of cGMP degradation using the PDE5 inhibitor Sildenafil did preserve vascular and alveolar growth in the hyperoxic rat BPD model. This beneficial effect might have been through promotion of lung angiogenesis, since in vitro, Sildenafil preserved endothelial network formation in hyperoxia. Further investigation is needed to reveal the precise mechanism by which Sildenafil is lung protective and whether this is exclusively through promoting lung angiogenesis (and therefore alveolar development) or whether Sildenafil or the NO/cGMP pathway also has a direct effect on alveolar epithelial cell growth.
We found that hyperoxic rat pups had increased cGMP plasma levels to control rats. This finding is consistent with other studies in which increases in lung NO synthase and cGMP levels were seen in hyperoxic rats compared to normoxic rats (46) . In the latter study, NO synthase blockade reduced lung cGMP levels in the hyperoxic rat pups but did not reverse the pathologic consequences of hyperoxic exposure (46) . In our study, Sildenafil further increased cGMP levels in hyperoxic rats and attenuated hyperoxic-induced lung injury. Thus, one possible interpretation is that upregulation of cGMP in hyperoxia may be a compensatory mechanism to counteract the deleterious effects of oxygen on lung development. By analogy, cGMP levels are increased in monocrotalline-induced pulmonary hypertension and treatment with E4010, another PDE5
inhibitor further enhances cGMP levels (47) . In our study, Sildenafil further increased cGMP levels and this may have been enough to promote lung angiogenesis/alveolar growth in hyperoxic conditions. This further assumes that the NO/cGMP pathway is crucial for alveolar development. Pulmonary hypertension can contribute to morbidity and mortality in human BPD (7) . The hyperoxic BPD model in rats also exhibits pulmonary hypertension characterized by increased pulmonary vasoconstriction, RVH and MWT of pulmonary arteries. Decreased NO and excessive reactive oxygen species and endothelin pathway activation may account for pulmonary hypertension in this model (51) (52) (53) . Sildenafil alleviated pulmonary hypertension in our animal model. This is consistent with studies showing beneficial hemodynamic and structural effects of Sildenafil in various adult animal models (54, 55) and in humans (56-59) with pulmonary hypertension. Sildenafil is currently being investigated in newborns in clinical trials for persistent pulmonary hypertension, just like inhaled NO ten years ago.
In conclusion, this is the first report on the potential therapeutic benefit of Sildenafil in protecting from oxygen-induced alveolar damage. The relative pulmonary vascular specificity of Sildenafil, its low cost, and its post-marketing safety makes it an attractive therapeutic option, and warrants further study. Clinical trials are indicated to determine whether Sildenafil can decrease the incidence/severity of BPD in premature infants and potentially other lung diseases characterized by alveolar damage. Capillary density, as quantified by the number of barium-filled pulmonary arteries counted per high-power field, was significantly decreased in hyperoxic-exposed lungs compared to room airexposed lungs. Treatment with Sildenafil preserved lung capillary density in experimental BPD. Hyperoxic-exposed rats had significant RVH as indicated by the increase in RV/LV+S ratio compared to normoxic controls. Sildenafil treatment reduced RVH. C. Medial wall thickness.
Legends
Representative picture of pulmonary arteries displaying a thickened medial arterial wall in hyperoxic rat lungs as compared with normoxic controls. Sildenafil treatment significantly reduced the % MWT as compared with untreated hyperoxic pulmonary arteries. The concentration of cGMP increases in the plasma of hyperoxic rats. cGMP levels further increased in Sildenafil-treated hyperoxic rats.
